RxDoctor Payments Data

Naomi Fukuda, APRN

Medical-Surgical · Ewa Beach, HINPI 1629471834

Payments from drug & device makers

$11,183in general payments, 2019–2025

Across 454 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Dexcom, Inc.$2K
  • Lilly USA, LLC$2K
  • Abbott$2K
  • Bayer$974
  • Mannkind Corporation$409
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$10,79797%
  • Education$3863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical-surgical providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$26,912
Medicare patients
110
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide310$585,754
JardianceEmpagliflozin152$225,997
KorlymMifepristone12$224,708
MounjaroTirzepatide120$224,102
RybelsusSemaglutide77$182,621
Tresiba Flextouch U-100Insulin Degludec144$86,744
TrulicityDulaglutide32$68,606
Tresiba Flextouch U-200Insulin Degludec56$46,237
TradjentaLinagliptin25$33,452
FarxigaDapagliflozin Propanediol26$31,556
Humulin R U-500 KwikpenInsulin Regular, Human21$31,179
JanuviaSitagliptin Phosphate18$29,973
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$23,555
Nano 2nd Gen Pen NeedlePen Needle, Diabetic187$14,409
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$10,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$2,502$771,473399 claims
Lilly USA, LLCMounjaro, Trulicity$1,955$292,708152 claims
Boehringer IngelheimJardiance, Tradjenta$395$259,449177 claims
Corcept TherapeuticsKorlym$241$224,70812 claims
AstraZenecaFarxiga$141$31,55626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical-surgical providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other medical-surgical in Ewa Beach

Where these figures come from

Is this you, or does something look wrong? →